Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics
about
Atypical antipsychotics for psychosis in adolescentsAtypical antipsychotics for psychosis in adolescentsA systematic examination of brain volumetric abnormalities in recent-onset schizophrenia using voxel-based, surface-based and region-of-interest-based morphometric analysesEfficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysisDrug-induced supersensitivity psychosis revisited: characteristics of relapse in treatment-compliant patientsA theory of mind investigation into the appreciation of visual jokes in schizophreniaThe effect of verbalization strategy on Wisconsin Card Sorting Test performance in schizophrenic patients receiving classical or atypical antipsychotics.Increased Resting-State Gamma-Band Connectivity in First-Episode SchizophreniaThe Efficacy of Non-Pharmacological Interventions on Brain-Derived Neurotrophic Factor in Schizophrenia: A Systematic Review and Meta-AnalysisPsychotropic dose equivalence in JapanA longitudinal study of alterations of hippocampal volumes and serum BDNF levels in association to atypical antipsychotics in a sample of first-episode patients with schizophreniaThe effect of repetitive transcranial magnetic stimulation on gamma oscillatory activity in schizophreniaActivation and Functional Connectivity of the Left Inferior Temporal Gyrus during Visual Speech Priming in Healthy Listeners and Listeners with Schizophrenia.Amusia and protolanguage impairments in schizophrenia.Parkinsonian motor impairment predicts personality domains related to genetic risk and treatment outcomes in schizophrenia.Mild expression differences of MECP2 influencing aggressive social behavior.A neurophysiological deficit in early visual processing in schizophrenia patients with auditory hallucinations.Gamma band neural synchronization deficits for auditory steady state responses in bipolar disorder patientsAmygdala recruitment in schizophrenia in response to aversive emotional material: a meta-analysis of neuroimaging studiesProspective cohort study of the relationship between neuro-cognition, social cognition and violence in forensic patients with schizophrenia and schizoaffective disorder.Metacognitive training for delusions (MCTd): effectiveness on data-gathering and belief flexibility in a Chinese sample.Conformance to schizophrenia treatment guidelines in North West-Bank, Palestine: focus on antipsychotic dosing and polytherapy.The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia.The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample.Isoform specific differences in phospholipase C beta 1 expression in the prefrontal cortex in schizophrenia and suicideEffects of domain-specific noise on visual motion processing in schizophrenia.Event-related brain potentials to emotional images and gonadal steroid hormone levels in patients with schizophrenia and paired controls.Cortical thinning in temporo-parietal junction (TPJ) in non-affective first-episode of psychosis patients with persistent negative symptomsPostural control in bipolar disorder: increased sway area and decreased dynamical complexity.Eluding the illusion? Schizophrenia, dopamine and the McGurk effectNeuroanatomical circuitry associated with exploratory eye movement in schizophrenia: a voxel-based morphometric study.Convergent evidence from multimodal imaging reveals amygdala abnormalities in schizophrenic patients and their first-degree relativesReduced left uncinate fasciculus fractional anisotropy in deficit schizophrenia but not in non-deficit schizophrenia.Structural alterations of the social brain: a comparison between schizophrenia and autism.Deficits in agency in schizophrenia, and additional deficits in body image, body schema, and internal timing, in passivity symptoms.Reduced gray to white matter tissue intensity contrast in schizophrenia.Association of catechol-O-methyltransferase gene polymorphisms with schizophrenia and negative symptoms in a Chinese population.Eye-head coordination abnormalities in schizophrenia.Inferring reward prediction errors in patients with schizophrenia: a dynamic reward task for reinforcement learningMTHFR 677C>T effects on anterior cingulate structure and function during response monitoring in schizophrenia: a preliminary study
P2860
Q24197475-09B99A8E-DC36-409E-9A27-E201B63CF6D2Q24203954-4C898363-01C0-4995-9EA0-FB40BC08CC79Q24288871-7AE20471-4FAB-4EFB-9950-66DA6601098EQ24606868-FA6BCF3E-5730-4058-8DBF-177DDFE5E22AQ24633061-E6FA1354-10D5-4A42-A9A7-F2D4C2EFD559Q24801147-3F4E37FD-FE94-4132-82F5-2FAA94125833Q25256710-6A7803C7-21D1-49D4-BF09-6E859D810A13Q27320037-92A0D1BF-8338-43F0-B1B0-22B0446E17D9Q28066603-F42EEA7D-5D33-485F-A3BF-900C2FD783A9Q28080652-0859C97D-6DFC-4FAD-AAF1-9186F4033FCAQ28539784-B4D1EB16-DD27-43DC-BB80-D9EDE21F7E1EQ28742079-B1E12C3D-50C9-47E5-957E-A162377A3BFFQ30360113-DA9BE638-E4A1-4AAF-81D9-BD8D0EF97CCBQ30360155-CCD7F9F1-0254-40B4-BDDE-896F7D2864B9Q30365000-B5C91C23-721A-4619-AC3A-312EE6E2ABA5Q30438103-57B2D914-F608-4880-BC67-31613854CCE8Q30450069-43C37E08-7E4C-48AB-A83B-86B52B51D99FQ30465769-192B6E7A-A21E-419C-A5E7-F7D22BAE294EQ30513499-CD28AC3F-E9A3-4856-8861-96643FCDBB4FQ30657237-53A9C211-C31C-4EC7-B355-290B4D9685AEQ30977624-005B59D1-75BD-49DD-A467-70F7699984C2Q33455799-2DC78215-3594-4669-B874-E076908F5522Q33605308-37A89AB7-5060-4D51-8611-1BE4798AB56BQ33641039-377F4C63-EAE8-44CB-A0FC-3CD20A7DF671Q33718808-668C503C-917B-42B3-885D-49CBCA125496Q33734083-3FF4BFAA-5906-4BE4-BBC9-6819775C5B47Q33737973-FF3E81AE-E20F-42A6-AC7A-3B8CB79BA825Q33826006-09C428C0-05C5-4E8B-86EA-468725B9BDFAQ33911062-97A647C2-B2AF-435F-ABB1-7C6C855EA318Q34003856-797DD17D-451D-4C90-8920-341CE8737A20Q34047121-C377CDAA-3423-49AA-ADBA-3A02D1C2AF15Q34103384-9FE18FA7-DE8A-491C-9940-03C733AD5AE6Q34129176-7E4BCDF7-AC63-4EF1-9BFC-DC16B7AADA0AQ34133941-1A6A1EB7-24CC-4082-88DC-B5452BC19CAFQ34159092-67801F0E-8074-4F13-B80A-5AEBBD9C9CE7Q34277636-008273D8-846C-4F82-8B8B-4926A1D5EC24Q34310366-CB50ADD9-AC7F-4AF2-853A-E11C99779D04Q34371549-8B2B4557-2DA3-4AF5-8739-96709B85DBA0Q34488198-AE8D9401-EB27-4384-93C1-11DB5232F056Q34498919-45289AC2-2098-4058-9699-4CC58A523C81
P2860
Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics
description
im Juni 2003 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в червні 2003
@uk
name
Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics
@en
Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics
@nl
type
label
Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics
@en
Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics
@nl
prefLabel
Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics
@en
Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics
@nl
P356
P1476
Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics
@en
P2093
Scott W. Woods
P304
P356
10.4088/JCP.V64N0607
P577
2003-06-15T00:00:00Z